Scientists have long struggled to target proteins that lack defined structure and are involved in cancer, neurodegenerative ...

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

Given the central role of p53, Myc, and MCL1 in cancer progression ... proteins of interest and have clinically relevant substrate degradation profiles offering broad therapeutic opportunities.

Neuroblastomas are the most common cancer in infants, with about 700–800 diagnoses per year in the US, according to the American Cancer Society. Some of the most high-risk cases are driven by elevated ...

"Because Aurora-A stabilizes N-Myc against degradation, inhibiting the interaction could represent a promising approach for anticancer drug development and our finding that peptidomimetics can ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...